1.  

Article types	Original article
Language	English
Refereed paper	Refereed
Title	The efficacy and toxicity of cabazitaxel for treatment of docetaxel-resistant prostate cancer correlating with the initial doses in Japanese patients.
Journal	Formal name：BMC cancer Abbreviation：BMC Cancer ISSN code：1471-2407(Electronic)1471-2407(Linking)
Domestic / Foregin	Foregin
Volume, Number, Page	19(1),pp.156
Papers・Author	Terada Naoki, Kamoto Toshiyuki, Tsukino Hiromasa, Mukai Shoichiro, Akamatsu Shusuke, Inoue Takahiro, Ogawa Osamu, Narita Shintaro, Habuchi Tomonori, Yamashita Shinichi, Mitsuzuka Koji, Arai Yoichi, Kandori Shuya, Kojima Takahiro, Nishiyama Hiroyuki, Kawamura Yoshiaki, Shimizu Yuki, Terachi Toshiro, Sugi Motohiko, Kinoshita Hidefumi, Matsuda Tadashi, Yamada Yusuke, Yamamoto Shingo, Hirama Hiromi, Sugimoto Mikio, Kakehi Yoshiyuki, Sakurai Toshihiko, Tsuchiya Norihiko
Publication date	2019/02
Papers・Description	BACKGROUND:We analyzed the efficacy and toxicity of cabazitaxel (CBZ) at high and low initial doses in Japanese patients with docetaxel-resistant castration-resistant prostate cancer (CRPC).METHODS:We retrospectively evaluated 118 patients who received CBZ for docetaxel-resistant CRPC in 10 university hospitals in Japan between 2014 and 2016. The rate of decrease of prostate-specific antigen (PSA), adverse events, progression-free survival (PFS), and overall survival (OS) were compared between patients receiving initially high (≥22.5 mg/m2RESULTS:PSA values decreased by> 50% in 22 patients (19%), with a higher frequency in the high-dose group than in the low-dose group (29 and 14%, P = 0.073).
DOI	10.1186/s12885-019-5342-9
PMID	30770773